Results 111 to 120 of about 14,946 (248)

TRPML1 agonist ML‐SA5 attenuates pulmonary fibroblast activation by suppressing mTOR and restoring autophagic flux

FEBS Open Bio, EarlyView.
TGF‐β1 stimulation downregulates lysosomal channel TRPML1 in pulmonary fibroblasts. The TRPML1 agonist ML‐SA5 suppressed fibroblast‐to‐myofibroblast activation and collagen production. Mechanistically, ML‐SA5 inhibited mTOR phosphorylation, restored autophagic flux, and its effects were enhanced by rapamycin (mTOR inhibitor) and reversed by MHY1485 ...
Jiatong Yao, Xiaoting Kang, Lulu Meng, Shaoxuan Zhang, Qiujie Li, Jinyu Zhou, Mengyue Xue, Chu Li, Hua Zhu, Pengzhou Hang, Jing Zhao   +10 more
wiley   +1 more source

Ten simple rules for preparing a job application for an academic position. [PDF]

PLoS Comput Biol
Peña-Castillo L, Meruvia-Pastor O.
europepmc   +1 more source

Using fluorescence fluctuation spectroscopy to quantify molecular dynamics within cells

FEBS Open Bio, EarlyView.
Microscopy techniques like fluorescence correlation spectroscopy (FCS) and number and brightness analysis (N&B) allow to quantify concentrations, diffusion rates, and oligomerization of fluorescently labeled molecules in the living cell. In this protocol the principles of how to set up these types of experiments are described including calibration ...
Mark A. Hink
wiley   +1 more source

TiO₂-coated guided-mode resonance gratings for polarization-selective green light filtering. [PDF]

Discov Nano
Aslam K, Mushtaq N, Chai Y, Kang G.
europepmc   +1 more source

Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl‐2 and Mcl‐1 blockade in preclinical glioblastoma models

FEBS Open Bio, EarlyView.
The PAM pathway and its impact on cellular metabolism. Color‐coded key symbols represent Rapamycin (R, orange, targeting mTOR) and Dactolisib (D, green, targeting PI3K/mTOR), indicating their sites of action. Created with BioRenders.com. Glioblastoma resists therapy through interconnected survival programs.
Kai Zhao, Leonie Meyer, Madita Braun, Katharina Otte, Celine Bitter, Maite Pawlik, Hartmann Raifer, Frederik Helmprobst, Axel Pagenstecher, Hans Urban, Michael C. Burger, Michael W. Ronellenfitsch, Joachim P. Steinbach, Jarmila Jedelská, Shamim Bagheri, Behrooz H. Yousefi, Pietro Di Fazio, Markus Luster, Andreas H. Mahnken, Andreas Neubauer, Andreas Burchert, Christopher Nimsky, Jörg W. Bartsch, Tillmann Rusch   +23 more
wiley   +1 more source

Perpetual Futures for Stocks: The SpaceX Pre-IPO Market. [PDF]

Entropy (Basel)
Gupta A, Polson NG.
europepmc   +1 more source

GBS‐MeDIP: A method for the simultaneous identification of genetic and epigenetic variants in tumors

FEBS Open Bio, EarlyView.
GBS‐MeDIP combines DNA sequencing with enrichment of methylated DNA to profile genetic and epigenetic variation in the same reduced genomic fraction. Applied to gastric cancer and parathyroid tumors, it identifies sequence variants, copy number changes, and differentially methylated regions together, helping distinguish true epigenetic changes from ...
Fábio Pértille, Shiva Rezaei, Julia Uffenorde, Oliver Gimm, Mohammad Ali Hosseinpour Feizi, Luiz Lehmann Coutinho, Carlos Guerrero‐Bosagna   +6 more
wiley   +1 more source

Language models transmit behavioural traits through hidden signals in data. [PDF]

Nature
Cloud A, Le M, Chua J, Betley J, Sztyber-Betley A, Mindermann S, Hilton J, Marks S, Evans O.   +8 more
europepmc   +1 more source

Rationally engineered polymeric interfaces for selective and dynamic recognition of vesicular agents

FEBS Open Bio, EarlyView.
This review explores how molecularly imprinted polymers can be engineered to recognize complex nanoscale vesicles, including extracellular vesicles and membrane‐enveloped viruses. By tailoring polymer cavities to vesicle surface chemistry and structure, these synthetic receptors support selective detection, separation, and integration with optical ...
Özgecan Erdem, Eylul Gulsen Yilmaz, Selcan Genc, Nil Kılıç, Fatih Inci   +4 more
wiley   +1 more source

Robust optimal reinsurance and ESG investment under rating-innovation ambiguity and ESG rating uncertainty. [PDF]

PLoS One
Fu J, Zhu G, Zhou G.
europepmc   +1 more source